À PROPOS DE CET ÉPISODE
Dr Ehninger (University Hospital Dresden, Dresden, Germany) presents on the results of a phase II randomised study on the safety and efficacy of sorafenib in leukaemia at a press conference at EHA 2015.
Anglais
États-Unis
TRANSCRIPTION 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
RECHERCHER LES ÉPISODES PASSÉS
Rechercher les épisodes précédents de EHA 2015.
AUTRES ÉPISODES DANS CE PODCAST
At a press conference at EHA 2015, Dr Mesa (Mayo Clinic Cancer Center, Scottsdale, USA) presented new data from the Phase 3 PERSIST-1 study which showed that pacritinib is more effective than the best available therapy (BAT) at improving disease symptoms and quality of life (QoL) for patients with …
Dr Hoffmann (Ludwig Maximilian University, Munich, Germany) talks to ecancertv at EHA 2015 about a web-based registry to record all newly-diagnosed chronic myeloid leukaemia (CML) patients in 20 European countries or pre-specified regions covering overall 92.5 million inhabitants.
The researchers …
Prof Anton Hagenbeek (Prof Anton Hagenbeek - University Medical Center Utrecht, Utrecht, Netherlands) talks to ecancertv at EHA 2015 about immunoconjugates, the latest targeted treatments in Hodgkin's lymphoma. He also suggests that patients with Hodgkin's disease partake in clinical trials.
ecan…
Dr Olga Guryanova (Memorial Sloan Kettering Cancer Center, New York, USA) presents, at a press conference at EHA 2015, the findings of her work looking at the role of mutant DNMT3A in acute myeloid leukaemia (AML) pathogenesis and chemoresistance.
Avertissement: Le podcast et les illustrations intégrés sur cette page proviennent de ecancer, qui est la propriété de son propriétaire et n'est ni affilié ni approuvé par Listen Notes, Inc.
MODIFIER
Merci de nous avoir aidé à tenir la base de données de podcasts à jour.
